{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:52:19Z","timestamp":1792108339668,"version":"4.4.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81803019"],"award-info":[{"award-number":["81803019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sichuan Science and Technology Program","award":["2022YFS0625"],"award-info":[{"award-number":["2022YFS0625"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the effectiveness of various medications for the treatment of endometriosis-related pain through a network meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SOURCES:<\/jats:title>\n            <jats:p>A comprehensive search was conducted in PubMed, Embase, Web of Science, and the Cochrane Controlled Trials Register until July 22, 2024. We also searched ClinicalTrials.gov for additional data on recently completed trials or potentially eligible randomized controlled trials (RCTs) but found nothing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS OF STUDY SELECTION:<\/jats:title>\n            <jats:p>The analysis included randomized RCTs that used pharmacologic interventions for managing endometriosis-related pain. The primary efficacy outcome was endometriosis-associated pelvic pain, which included dysmenorrhea, dyspareunia, and nonmenstrual pelvic pain. The analysis adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n            <jats:p>A total of 31 RCTs involving 8,665 patients were included in the analysis. In terms of endometriosis-associated pelvic pain, four interventions demonstrated significantly greater efficacy compared with placebo: leuprolide combined with combined oral contraceptive pills (OCPs) (standardized mean difference [SMD] \u22121.40, 95% CI, \u22122.41 to \u22120.38), dienogest (SMD \u22121.20, 95% CI, \u22121.78 to \u22120.61), leuprolide alone (SMD \u22121.05, 95% CI, \u22121.64 to \u22120.45), and combined OCP (SMD \u22120.67, 95% CI, \u22121.25 to \u22120.09). Leuprolide combined with combined OCP emerged as the most effective treatment modality. In addition, elagolix and the combination of vitamin C and vitamin E were identified as the most effective interventions for dysmenorrhea and dyspareunia. For nonmenstrual pelvic pain, gestrinone demonstrated superior efficacy compared with placebo and all other interventions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>This network meta-analysis indicates that leuprolide in combination with combined OCP, elagolix, vitamins C and E, and gestrinone may represent the most effective therapeutic options for alleviating endometriosis-associated pelvic pain, dysmenorrhea, dyspareunia, and nonmenstrual pelvic pain. These findings enhance our understanding of the relative efficacy of treatment strategies for pain associated with endometriosis. Future research should focus on conducting larger-scale and rigorously designed clinical trials within the target patient populations to further validate these results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000005923","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T17:03:26Z","timestamp":1747328606000},"page":"e23-e35","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacologic Interventions for Endometriosis-Related Pain"],"prefix":"10.1097","volume":"146","author":[{"given":"Liqiu","family":"Kou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjie","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"R1-20250717","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.3390\/ijms25137068","article-title":"New potential pharmacological options for endometriosis associated pain","volume":"25","author":"Garc\u00eda-Izquierdo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R2-20250717","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(21)00389-5","article-title":"Endometriosis is a chronic systemic disease: clinical challenges and novel innovations","volume":"397","author":"Taylor","year":"2021","journal-title":"Lancet"},{"key":"R3-20250717","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/biolre\/ioz016","article-title":"Endometriosis biomarkers: will codevelopment in academia-industry partnerships result in new and robust noninvasive diagnostic tests?","volume":"101","author":"D'Hooghe","year":"2019","journal-title":"Biol Reprod"},{"key":"R4-20250717","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(04)17403-5","article-title":"Endometriosis","volume":"364","author":"Giudice","year":"2004","journal-title":"Lancet"},{"key":"R5-20250717","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/AOG.0000000000005448","article-title":"Evaluation and management of endometriosis in the adolescent","volume":"143","author":"Shim","year":"2024","journal-title":"Obstet Gynecol"},{"key":"R6-20250717","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrendo.2013.255","article-title":"Endometriosis: pathogenesis and treatment","volume":"10","author":"Vercellini","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"R7-20250717","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12905-021-01500-4","article-title":"Effect of physical activity and exercise on endometriosis-associated symptoms: a systematic review","volume":"21","author":"Tennfjord","year":"2021","journal-title":"BMC Womens Health"},{"key":"R8-20250717","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/13543784.2018.1471135","article-title":"Investigational drugs for the treatment of endometriosis, an update on recent developments","volume":"27","author":"Barra","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"R9-20250717","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/dead263","article-title":"Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study","volume":"39","author":"Becker","year":"2024","journal-title":"Hum Reprod"},{"key":"R10-20250717","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.fertnstert.2017.01.003","article-title":"Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills","volume":"107","author":"Casper","year":"2017","journal-title":"Fertil Steril"},{"key":"R11-20250717","doi-asserted-by":"crossref","first-page":"11342","DOI":"10.3390\/ijms222111342","article-title":"GnRH antagonists with or without add-back therapy: a new alternative in the management of endometriosis?","volume":"22","author":"Donnez","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R12-20250717","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R13-20250717","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R14-20250717","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R15-20250717","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12905-024-03188-8","article-title":"Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study","volume":"24","author":"Parke","year":"2024","journal-title":"BMC Womens Health"},{"key":"R16-20250717","doi-asserted-by":"crossref","first-page":"630.e1","DOI":"10.1016\/j.ajog.2024.06.040","article-title":"Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial","volume":"231","author":"Miller","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"R17-20250717","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/humrep\/deae076","article-title":"Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, phase 3 study (EDELWEISS 3)","volume":"39","author":"Donnez","year":"2024","journal-title":"Hum Reprod"},{"key":"R18-20250717","doi-asserted-by":"crossref","first-page":"670","DOI":"10.34172\/aim.2021.96","article-title":"Comparing the effect of dienogest and OCPS on pain and quality of life in women with endometriosis: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Niakan","year":"2021","journal-title":"Arch Iran Med"},{"key":"R19-20250717","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ijgo.13677","article-title":"A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis","volume":"156","author":"Mehdizadeh Kashi","year":"2022","journal-title":"Int J Gynaecol Obstet"},{"key":"R20-20250717","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/09513590.2020.1807502","article-title":"Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study","volume":"37","author":"Zhao","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"R21-20250717","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.fertnstert.2021.11.013","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study","volume":"117","author":"Harada","year":"2022","journal-title":"Fertil Steril"},{"key":"R22-20250717","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study","volume":"115","author":"Osuga","year":"2021","journal-title":"Fertil Steril"},{"key":"R23-20250717","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.fertnstert.2020.02.114","article-title":"Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil Steril"},{"key":"R24-20250717","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejogrb.2021.10.029","article-title":"Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: randomized clinical trial","volume":"267","author":"El Taha","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R25-20250717","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/humrep\/dep469","article-title":"Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial","volume":"25","author":"Strowitzki","year":"2010","journal-title":"Hum Reprod"},{"key":"R26-20250717","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.fertnstert.2018.07.003","article-title":"Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial","volume":"110","author":"Carvalho","year":"2018","journal-title":"Fertil Steril"},{"key":"R27-20250717","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.12659\/MSM.901838","article-title":"Effects of vitamin D on endometriosis-related pain: a double-blind clinical trial","volume":"22","author":"Almassinokiani","year":"2016","journal-title":"Med Sci Monit"},{"key":"R28-20250717","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.fertnstert.2017.07.1165","article-title":"Ethinylestradiol 20 \u03bcg\/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial","volume":"108","author":"Harada","year":"2017","journal-title":"Fertil Steril"},{"key":"R29-20250717","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.fertnstert.2011.01.027","article-title":"Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain","volume":"95","author":"Guzick","year":"2011","journal-title":"Fertil Steril"},{"key":"R30-20250717","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1477-7827-9-88","article-title":"Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial","volume":"9","author":"Ferrero","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"key":"R31-20250717","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5301\/je.5000157","article-title":"Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study","volume":"5","author":"Carr","year":"2013","journal-title":"J Endometr Pelvic Pain Disord"},{"key":"R32-20250717","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s13224-018-1119-3","article-title":"Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis","volume":"68","author":"Abdou","year":"2018","journal-title":"J Obstet Gynaecol India"},{"key":"R33-20250717","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.fertnstert.2007.08.051","article-title":"Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial","volume":"90","author":"Harada","year":"2008","journal-title":"Fertil Steril"},{"key":"R34-20250717","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.fertnstert.2004.03.062","article-title":"Add-back therapy in the treatment of endometriosis-associated pain","volume":"82","author":"Zupi","year":"2004","journal-title":"Fertil Steril"},{"key":"R35-20250717","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0015-0282(16)56039-7","article-title":"A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis","volume":"60","author":"Vercellini","year":"1993","journal-title":"Fertil Steril"},{"key":"R36-20250717","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0015-0282(16)58682-8","article-title":"Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study: Gestrinone Italian Study Group","volume":"66","year":"1996","journal-title":"Fertil Steril"},{"key":"R37-20250717","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/humrep\/dez028","article-title":"Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study","volume":"34","author":"D'Hooghe","year":"2019","journal-title":"Hum Reprod"},{"key":"R38-20250717","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"R39-20250717","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)","volume":"399","author":"Giudice","year":"2022","journal-title":"Lancet"},{"key":"R40-20250717","doi-asserted-by":"crossref","first-page":"5529741","DOI":"10.1155\/2021\/5529741","article-title":"The effect of combined vitamin C and vitamin E supplementation on oxidative stress markers in women with endometriosis: a randomized, triple-blind placebo-controlled clinical trial","volume":"2021","author":"Amini","year":"2021","journal-title":"Pain Res Manag"},{"key":"R41-20250717","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/09513590.2021.1878138","article-title":"The effect of vitamin D supplementation on clinical symptoms and metabolic profiles in patients with endometriosis","volume":"37","author":"Mehdizadehkashi","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"R42-20250717","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/ajcn\/nqaa096","article-title":"Supplementation with vitamin D or \u03c9-3 fatty acids in adolescent girls and young women with endometriosis (SAGE): a double-blind, randomized, placebo-controlled trial","volume":"112","author":"Nodler","year":"2020","journal-title":"Am J Clin Nutr"},{"key":"R43-20250717","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/1933719113497292","article-title":"Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study","volume":"21","author":"Diamond","year":"2014","journal-title":"Reprod Sci"},{"key":"R44-20250717","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12958-023-01126-1","article-title":"Antioxidant vitamins supplementation reduce endometriosis related pelvic pain in humans: a systematic review and meta-analysis","volume":"21","author":"Zheng","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"key":"R45-20250717","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00404-022-06862-0","article-title":"Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis","volume":"308","author":"Xin","year":"2023","journal-title":"Arch Gynecol Obstet"},{"key":"R46-20250717","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001019.pub3","article-title":"Oral contraceptives for pain associated with endometriosis","author":"Brown","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R47-20250717","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.fertnstert.2016.10.022","article-title":"Estrogen-progestins and progestins for the management of endometriosis","volume":"106","author":"Vercellini","year":"2016","journal-title":"Fertil Steril"},{"key":"R48-20250717","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jwh.2019.8096","article-title":"A clinician's guide to the treatment of endometriosis with elagolix","volume":"30","author":"Leyland","year":"2021","journal-title":"J Womens Health (Larchmt)"},{"key":"R49-20250717","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2008-1695","article-title":"Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix","volume":"94","author":"Struthers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-20250717","doi-asserted-by":"crossref","first-page":"e0301867","DOI":"10.1371\/journal.pone.0301867","article-title":"Vitamin C and E antioxidant supplementation may significantly reduce pain symptoms in endometriosis: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Bayu","year":"2024","journal-title":"PLoS One"},{"key":"R51-20250717","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.trsl.2012.05.001","article-title":"Antioxidant supplementation reduces endometriosis-related pelvic pain in humans","volume":"161","author":"Santanam","year":"2013","journal-title":"Transl Res"},{"key":"R52-20250717","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/humupd\/dmv059","article-title":"GnRH and GnRH receptors in the pathophysiology of the human female reproductive system","volume":"22","author":"Maggi","year":"2016","journal-title":"Hum Reprod Update"},{"key":"R53-20250717","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0015-0282(16)60969-X","article-title":"Endocrine, metabolic, and clinical effects of gestrinone in women with endometriosis","volume":"52","author":"Venturini","year":"1989","journal-title":"Fertil Steril"},{"key":"R54-20250717","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3390\/ph17091248","article-title":"Effects, doses, and applicability of gestrinone in estrogen-dependent conditions and post-menopausal women","volume":"17","author":"Renke","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R55-20250717","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mce.2009.03.022","article-title":"Estrogen metabolism and action in endometriosis","volume":"307","author":"Rizner","year":"2009","journal-title":"Mol Cel Endocrinol"},{"key":"R56-20250717","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.metabol.2017.11.018","article-title":"The hypothalamus-pituitary-gonad axis: tales of mice and men","volume":"86","author":"Kaprara","year":"2018","journal-title":"Metabolism"},{"key":"R57-20250717","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/DDDT.S269976","article-title":"Profile of linzagolix in the management of endometriosis, including design, development and potential place in therapy: a narrative review","volume":"17","author":"Donnez","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"R58-20250717","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/humupd\/dmaa040","article-title":"Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses","volume":"27","author":"Ata","year":"2021","journal-title":"Hum Reprod Update"},{"key":"R59-20250717","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1210\/endo-127-1-319","article-title":"In vivo and in vitro modulation of gonadotropin-releasing hormone metabolism by estradiol and progesterone","volume":"127","author":"Danforth","year":"1990","journal-title":"Endocrinology"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:01:50Z","timestamp":1752786110000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005923"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005923","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"2024-12-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}